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ABSTRACT
Objectives To determine the proportion of patients with 
extremity sarcoma who would be willing to participate 
in a clinical trial in which they would be randomised to 
one of four different postoperative sarcoma surveillance 
regimens. Additionally, we assessed patients’ perspectives 
on the burden of cancer care, factors that influence 
comfort with randomisation and the importance of cancer 
research.
Design Prospective, cross- sectional patient survey.
Setting Outpatient sarcoma clinics in Canada, the USA 
and Spain between May 2017 and April 2020. Survey data 
were entered into a study- specific database.
Participants Patients with extremity sarcoma who had 
completed definitive treatment from seven clinics across 
Canada, the USA and Spain.
Main outcome measures The proportion of patients with 
extremity sarcoma who would be willing to participate in 
a randomised controlled trial (RCT) that evaluates varying 
postoperative cancer surveillance regimens.
Results One hundred thirty complete surveys were 
obtained. Respondents reported a wide range of burdens 
related to clinical care and surveillance. The majority 
of patients (85.5%) responded that they would agree 
to participate in a cancer surveillance RCT if eligible. 
The most common reason to participate was that they 
wanted to help future patients. Those that would decline 
to participate most commonly reported that participating 
in research would be too much of a burden for them at a 
time when they are already feeling overwhelmed. However, 
most patients agreed that cancer research will help 
doctors better understand and treat cancer.
Conclusions These results demonstrate that most 
participants would be willing to participate in an RCT 
that evaluates varying postoperative cancer surveillance 
regimens. Participants’ motivation for trial participation 
included altruistic reasons to help future patients and 
deterrents to trial participation included the overwhelming 
burden of a cancer diagnosis. These results will help 
inform the development of patient- centred RCT protocols 
in sarcoma surveillance research.
Level of evidence V.
INTRODUCTION
Sarcomas are a rare and heterogenous group 
of cancers with distinct biology that represent 
<1% of all malignancies.1–6 Following treat-
ment for a sarcoma, patients remain at risk 
for the development of local and systemic 
disease recurrence, which necessitates careful 
postoperative surveillance. Almost 50% of all 
patients with sarcoma will develop a local 
or distant recurrence; however, the risk of 
recurrence is greatest in the first few years, 
with 68% occurring by 2 years and 90% by 
5 years.7–9 Metastasis to the lung is the most 
frequent single location of disease recur-
rence in patients with sarcoma, occurring 
in approximately one- half of all patients.9–12 
Earlier detection of less advanced and resect-
able disease relapse may prolong patient 
survival; however, once advanced metastases 
are detected, the median length of survival is 
12–15 months.9
As such, routine follow- up following the 
completion of sarcoma treatment is standard 
Strengths and limitations of this study
 ► The primary objective of this study was to investi-
gate the proportion of patients with extremity sarco-
ma who would be willing to participate in a clinical 
trial in which they would be randomised to one of 
four different postoperative cancer surveillance 
regimens.
 ► The results of this study have been used to directly 
inform the definitive phase of the Surveillance AFter 
Extremity Tumor SurgerY (SAFETY) trial.
 ► Patient engagement in the preliminary trial devel-
opment is expected to improve the trial’s relevance, 
increase transparency and, ultimately, accelerate 
the adoption of findings into practice.
 ► Patients who agreed to participate in the survey 
study may be more likely to participate in research 
in general, thus possibly introducing selection bias.
 ► This may have resulted in an overestimation of the 
acceptance rate of the SAFETY study and interest 
in clinical research; however, our response rate of 
















pen: first published as 10.1136/bm





2 Schneider P, et al. BMJ Open 2021;11:e042742. doi:10.1136/bmjopen-2020-042742
Open access 
practice, and generally entails regular visits to sarcoma 
outpatient clinics in the first 5–10 years after surgery. 
These visits typically include a clinical history, a physical 
examination and imaging of the lungs. Regular, intensive 
surveillance is more likely to identify recurrent disease 
earlier than would less intensive surveillance. This may 
provide reassurance to patients and clinicians as if the 
interval screening is negative, the patient is considered at 
that time to be disease- free.
However, the adverse effects of intensive surveillance 
practices on patients are also noteworthy. Intensive surveil-
lance can threaten the financial security of patients, due 
in part to the direct costs, including travel, accommoda-
tion, personal care and homemaking, and indirect costs, 
including lost wages for patients and their caregivers, 
incurred as a result of follow- up appointments.13 As a 
result, patients’ health and quality of life can be dramati-
cally impacted should they decide to forego further treat-
ment or alter their lifestyles in order to alleviate financial 
difficulties.13–15 Furthermore, intensive surveillance inves-
tigations can also induce anxiety, and earlier knowledge of 
disease recurrence may adversely impact patients’ psycho-
social well- being for those whose mortality risk cannot be 
significantly reduced by further medical interventions.16 
In fact, the first recommendation put forward by Choosing 
Wisely Canada for oncology is not to ‘order tests to detect 
recurrent cancer in asymptomatic patients if there is not 
a realistic expectation that early detection of recurrence 
can improve survival or quality of life’.17
A randomised controlled trial (RCT) would be the 
ideal approach to determine the optimal postopera-
tive surveillance strategy that balances potential gains 
in survival, costs and quality of life. Given the rarity of 
sarcoma, possible patient anxiety related to both less- 
intensive and more- intensive sarcoma surveillance and 
the fact that clinical trial recruitment is often slower 
than anticipated, such an RCT will require extensive 
international collaboration and patient willingness to 
be randomly allocated to varying surveillance regimens. 
Patients’ perceptions of surveillance and of participation 
in a surveillance RCT are required in order to develop 
a study protocol that is patient- centred, compelling and 
feasible, and is capable of answering this high priority 
clinical question in a reasonable timeframe.18 19 In this 
study, we conducted a patient survey to investigate the 
proportion of patients with extremity sarcoma that would 
be willing to participate in a clinical trial in which they 
would be randomised to one of four different postopera-
tive sarcoma surveillance regimens. We also assessed the 
burden of cancer care on patients, the factors that influ-
ence patient comfort with being randomised to different 
surveillance protocols and we explored patients’ views on 
the importance of cancer research.
METHODS
We conducted a cross- sectional multicentre survey 
between May 2017 and April 2020 at seven sarcoma 
outpatient clinics in Canada (three sites), the USA (three 
sites) and Spain (one site).
Participants
Clinical sites
The clinical sites within our international orthopaedic 
oncology research network were carefully screened 
for the following criteria: (1) sufficiently high sarcoma 
volume defined as ≥20 participants per year; (2) adequate 
research personnel and infrastructure to manage the 
study and (3) an interest in participating in the Surveil-
lance AFter Extremity Tumor surgerY (SAFETY) trial. The 
clinical sites that met the eligibility criteria were invited to 
participate in this cross- sectional study.
Patients
In order to be eligible for participation, patients must 
have: (1) been at least 18 years of age; (2) been able to 
read, understand and write in English, French or Spanish; 
(3) have recently completed treatment of an extremity 
sarcoma and (4) provided consent to participate.
Questionnaire objectives
Given that patients’ willingness to participate in cancer 
surveillance research is the ultimate determinant of 
overall study feasibility, the primary objective of this 
questionnaire was to determine whether patients with 
extremity sarcoma would be willing to participate in 
the SAFETY trial.20 The SAFETY trial, initiated in early 
2020, is a 2×2 factorial design RCT in which patients with 
sarcoma are randomised to one of four different surveil-
lance regiments. The primary objective of the SAFETY 
trial is to determine the effect of surveillance intensity on 
long- term survival in the soft- tissue sarcoma population. 
The current cross- sectional survey served as background 
work for the trial’s development.
The secondary objectives of this cross- sectional patient 
survey included: (1) assessment of the burden of cancer 
care on patients; (2) assessment of factors that influ-
ence patient comfort with being randomised to different 
surveillance protocols and (3) the exploration of patients’ 
views on the importance of cancer research.
Questionnaire development
Item generation
We developed a unique patient questionnaire for the 
purpose of this study. The development of this question-
naire was informed by a review of the current literature on 
patient surveillance and in consultation with experts in 
orthopaedic oncology, research methodology and patient 
recruitment. We utilised a ‘sampling- to- redundancy’ 
approach in which we solicited feedback from new ortho-
paedic oncologists and research methodologists until no 
new items for the questionnaire emerged.
Pretesting and validity assessments
The questionnaire was reviewed by nine additional 
experts, who were either orthopaedic oncologists 
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evaluated whether the questionnaire as a whole appeared 
to adequately address the question of whether patients 
with extremity sarcoma would participate in cancer 
surveillance research (face validity) and whether the indi-
vidual questions adequately addressed the objectives of 
the current study (content validity). These nine experts 
also assessed the questionnaire’s comprehensiveness and 
flow, as well as identified any redundant, irrelevant or 
poorly worded questions.
Survey description
The final survey comprised 58 questions using Likert 
scales, multiple choice and brief open- ended questions. 
The following sections were included: (a) demographics, 
including medical history and income; (b) cancer 
history, including the number of treatment visits thus far 
required; (c) perceptions of cancer research; (d) finan-
cial burden of cancer care; (e) logistical burden of cancer 
care and (f) the SAFETY trial, including perceptions of 
cancer surveillance, the trial design and willingness to 
participate in such a trial and reasons for accepting or 
declining to participate. The survey is provided in online 
supplemental appendix 1.
All questions were straightforward and used clear and 
layman terminology to enhance the validity of the results. 
The survey length was kept to a minimum in an effort 
to maximise the response rate and to limit barriers that 
could have affected its proper completion.
Sample size
Convenience sampling of consecutive patients was used at 
the seven participating sites. One hundred thirty patients 
completed the patient survey, which represents a robust 
sample in the study of rare diseases.21
Survey administration and data collection
Initially, we approached all patients with extremity 
sarcoma in person that had consented for sarcoma 
surgery. However, after consulting with the SAFETY trial’s 
Steering Committee members on the study’s protocol 
in May 2018, we determined that patients would be 
approached, consented and randomised into the SAFETY 
trial after definitive treatment for their extremity sarcoma, 
as it was deemed a less stressful time for patients to make 
an informed decision, as well as a time point closer to the 
initiation of surveillance. After this decision was made, we 
began approaching all recent postoperative patients with 
extremity sarcoma for participation in this survey study, 
either at a postoperative clinical appointment or via tele-
phone. After obtaining informed consent, the site study 
coordinator provided each participant with a paper copy 
of the questionnaire to complete in a private location. 
Participants were allowed to leave a question blank if they 
found it uncomfortable to answer. On completion, the 
participant returned the questionnaire to the site study 
coordinator who verified that all questions had been 
answered. Completed questionnaires were then entered 
into a study- specific database using the REDCap elec-
tronic data capture software system.
Statistical analysis
Descriptive analyses, including frequency counts and 
percentages, were calculated for all collected data. 
Continuous data were presented as means and SD.
Role of the funding source
The funding source had no role in the design or conduct 
of the study; the collection, management, analysis or 
interpretation of the data or the preparation, review or 
approval of the manuscript. None of the authors has been 
paid to write this article. The study team had full access to 
all of the study data and takes responsibility for the integ-
rity of the data and the accuracy of the data.
Patient and public involvement
Although this study evaluates the patients’ perspectives 
on participating in clinical trials and cancer research, 
patients were not involved in the design, conduct or 
reporting or dissemination of this research. However, the 
results of this study will help inform the development of 




A total of 142 patients were approached to complete the 
survey and 130 agreed (response rate 92%). To the best 
of our knowledge, no patients were missed during the 
recruitment period. Participant demographic and cancer 
history data are shown in Table 1. The mean participant 
age was 56.4 years (SD 16.9 years) and 60.8% of partici-
pants were male. The majority of patient respondents were 
white (82.3%) and country of residence was reported as 
Canada in 40.8%, the USA in 52.3% and Spain in 6.9% 
of respondents. Most respondents were married or in a 
common law relationship (70.5%). There was a broad 
range of educational levels reported with a high school 
diploma as the most common response (31.3%), and a 
wide range of household incomes were reported. The 
most common anatomic location for the sarcoma was 
the lower extremity (66.7%), and participants reported 
receiving multidisciplinary treatment including chemo-
therapy (21.9%) and radiotherapy (68.4%). Travel times 
to the clinic ranged evenly across the spectrum from 
<30 min to >2 hours. Most participants reported travelling 
to medical appointments by personal vehicle (75%) by 
themselves (46.9%) or with a spouse (41.4%). Seventy- 
five per cent of patient respondents reported not having 
previously been involved in a clinical research study.
Burden of cancer care
Respondent details for burden of cancer care are shown 
in table 2. The majority of participants reported at least 
some form of financial burden related to their cancer 
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Table 1 Participant demographics
Characteristic N=130
Age (years), mean (SD) 56.4 (16.9)
Gender, n (%)
  Male 79 (60.8)
  Female 51 (39.2)
Ethnicity, n (%)
  White/Caucasian 107 (82.3)
  Black 3 (2.3)
  Native 1 (0.8)
  Asian 4 (3.1)
  Hispanic 9 (6.9)
  Other (specify) 5 (3.8)
Country, n (%)
  Canada 53 (40.8)
  USA 68 (52.3)
  Spain 9 (6.9)
Marital status, n (%)
  Single 20 (15.5)
  Separated 0 (0)
  Divorced 11 (8.5)
  Common law 8 (6.2)
  Married 83 (64.3)
  Widowed 7 (5.4)
Highest level of education, n (%)
  Did not complete high school 11 (8.6)
  High school diploma 40 (31.3)
  College/Trade diploma 31 (24.2)
  Undergraduate degree 18 (14.1)
  Masters degree 11 (8.6)
  Doctorate degree 3 (2.3)
  Professional degree 7 (5.5)
Annual household income, n (%)*
  <$20 000 12 (9.8)
  $20 000–$39 999 25 (20.3)
  $40 000–$59 999 21 (17.1)
  $60 000–$79 999 13 (10.6)
  $80 000–$99 999 15 (12.2)
  $100 000 + 37 (30.1)
Cancer type, n (%)
  Chondrosarcoma 5 (3.9)
  Ewing’s sarcoma 1 (0.8)
  Fibrosarcoma 8 (6.3)
  Fibrous histiocytoma 2 (1.6)
  Leiomyosarcoma 4 (3.1)
  Liposarcoma 16 (12.6)
  Osteosarcoma 8 (6.3)
  Rhabdomyosarcoma 4 (3.1)
  Synovial sarcoma 11 (8.7)
Continued
Characteristic N=130
  Other 49 (38.6)
Location of tumour, n (%)
  Upper extremity 29 (22.5)
  Lower extremity 95 (73.6)
  Other 5 (3.9)
  Pelvis 2 (1.6)
  Trunk 3 (2.3)
Cancer treatment modalities, n (%)
  Chemotherapy 25 (21.9)
  Radiation therapy 78 (68.4)
  Physiotherapy 4 (3.5)
  Other 46 (40.4)
Travel time to sarcoma clinic, n (%)
  <30 min 24 (18.6)
  30–59 min 38 (29.5)
  60–89 min 19 (14.7)
  90–119 min 23 (17.8)
  120 min + 25 (19.4)
Primary mode of transportation to sarcoma clinic, n (%)
  Public transit 8 (6.5)
  Personal vehicle 93 (75.0)
  Taxi 3 (2.4)
  Bicycle 0 (0)
  Foot 1 (0.8)
  Hospital transportation 2 (1.6)
  Relative’s/Friend’s vehicle 13 (10.5)
  Other (specify) 4 (3.2)
Primary caregiver, n (%)
  Self 60 (46.9)
  Spouse/Partner 53 (41.4)
  Parent 8 (6.3)
  Sibling 1 (0.8)
  Child 5 (3.9)
  Grandchild 0 (0)
  Friend 1 (0.8)
  Other (specify) 0 (0)
Previous participation in research study, 
n (%)
  No 98 (75.4)
  Yes 32 (24.6)
  1 22 (71.0)
  2 8 (25.8)
  3 1 (3.2)
  >3 0 (0)
*Participants reporting household income in Euros (€) were converted 
to $C and placed in the respective group at the time of manuscript 
preparation. Reported household income values include both $C and 
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and travel expenses (87.7%), accommodation and meal 
expenses (76.6%), family and living expenses (78.9%), 
caregiving expenses (56.3%) and personal loss of wages 
(38%). Logistical burdens are also very significant for 
some participants. These included coordination of 
medical visits (46.5%), arrangement of time off work 
(31.5%) and arrangement of childcare when applicable.
The SAFETY trial: reasons to participate and views on cancer 
research
A summary of patients’ perceptions on cancer research 
and the SAFETY trial specifically are outlined in tables 3 
and 4. The most common reasons for agreeing to partic-
ipate in cancer research represented trust in the health-
care team and altruism: ‘I want to contribute to scientific 
research’ (79%), ‘I trust the doctor treating me’ (75%), 
“I believe the results from the study could benefit other 
patients in the future” (78.1%) and ‘I believe that the study 
offers the best treatment available’ (61.9%). With respect 
to overall views and perceptions of cancer research, 
approximately two- thirds of participants (68.7%) feel 
that they have a good understanding of clinical research. 
Notably, only about half (53.5%) are generally comfort-
able with the process of randomisation, in which their 
treatment or surveillance arm could be determined by 
chance. However, an overwhelming majority of partic-
ipants (128/130, 98.5%) strongly agree or agree that 
cancer research will help doctors better understand and 
treat cancer. In addition, 93.9% of respondents strongly 
agree or agree that the primary reason cancer research is 
done is to improve the treatment of future patients with 
cancer. Interestingly, over half of respondents (68/130, 
52.3%) strongly agree or agree that they would not 
benefit directly from participating from cancer research.
A total of 106 of 124 respondents that answered the ques-
tion ‘Would you participate in the SAFETY trial if eligible?’ 
reported that they would agree to participate (85.5%). 
Those that believed they would not agree to participate 
reported that they would decline for the following reasons: 
(1) ‘I do not believe that I can currently cope with the addi-
tional requirements of a research study’ (eight, respondents, 
44.4%), (2) “I have concerns about possibly being followed 




I believe that the study offers the best treatment 
available.
65 (61.9)
I want to contribute to scientific research. 83 (79.0)
I believe that the quality of care I receive would 
be better as part of this study.
42 (40.0)
I trust the doctor treating me. 79 (75.2)
I believe the benefits of participating would 
outweigh any negative side effects.
53 (50.5)
I believe the results from the study could benefit 
other patients in the future.
82 (78.1)
I believe that I would be monitored more closely 
as part of this study.
42 (40.0)
I think my cancer will get worse unless I 
participate in this study.
1 (1.0)
I had a positive experience in a previous 
research study.
6 (5.7)
Other (specify). 0 (0)
Table 2 Burden of cancer care
Burden n=130
Financial burdens
Transportation and travel expenses, n (%)
  No 16 (12.3)
  Yes 114 (87.7)
Accommodation and meal expenses, n (%)
  No 30 (23.4)
  Yes 98 (76.6)
Family and living expenses, n (%)
  No 27 (21.1)
  Yes 101 (78.9)
Caregiving expenses, n (%)
  No 56 (43.8)
  Yes 72 (56.3)
Personal loss of wages, n (%)
  Not applicable 40 (31.0)
  No 40 (31.0)
  Yes 49 (38.0)
Caregiver loss of wages, n (%)
  Not applicable 38 (29.9)
  No 62 (48.8)
  Yes 27 (21.3)
Logistical burdens
Coordination of frequent medical appointments, n (%)
  No 69 (53.5)
  Yes 60 (46.5)
Completion and submission of paperwork, n (%)
  Not applicable 20 (15.4)
  No 76 (58.5)
  Yes 34 (26.2)
Submission of medical bills, n (%)
  Not applicable 28 (21.5)
  No 61 (46.9)
  Yes 41 (31.5)
Arrangement of time off work, n (%)
  Not applicable 53 (40.8)
  No 36 (27.7)
  Yes 41 (31.5)
Arrangement of childcare, n (%)
  Not applicable 88 (67.7)
  No 27 (20.8)
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less intensively in this study” (four respondents, 22.2%), (3) 
“I have concerns about additional radiation exposures from 
CT scans” (four respondents, 22.2%) and (4) “I believe that 
the quality of care I receive would be inferior to what I would 
receive if I did not participate” (three respondents, 16.7%). 
Other less common reasons to decline the study included “I 
do not believe that the study offers the best treatment avail-
able”, “My family is not keen for me to participate” and travel 
and religious reasons. One respondent reported a negative 
experience with a previous trial.
DISCUSSION
Summary of findings
This study explored the perceptions of international patients 
with extremity sarcoma on cancer surveillance. We found 
that patients endure significant financial and logistical 
burdens associated with sarcoma care and follow- up. In 
general, patients are very interested in participating in clin-
ical research, and specifically in cancer surveillance research. 
The reasons for participating in research include the desire 
to help future patients and the perception that their care 
would be improved in the context of a clinical trial. However, 
some participants expressed a lingering concern with leaving 
their care and/or surveillance to chance (randomisation) 
and several indicated that they believe that they would not 
participate in research due to feeling overwhelmed with their 
cancer diagnosis and treatment. Overall, the results of this 
study will help inform the SAFETY trial and guide approaches 
to eligible patients when obtaining consent.
Strengths and limitations
This study has several strengths. First, we used a rigorous 
process for the development of the patient questionnaire 
and extensive piloting of the survey. This stepwise process 
created a questionnaire that was acceptable for patients and 
sufficiently clear and comprehensive to provide a robust 
dataset. Second, we surveyed patients across Canada, the 
USA and Spain. Although this required translation of English 
documents into French and Spanish, it provided a more 
global picture of patients’ perceptions. The SAFETY trial 
is an international endeavour, and therefore international 




I am interested in participating in clinical research related to 
my cancer.
  Strongly agree 63 (49.2)
  Agree 51 (39.8)
  Neither agree nor disagree 11 (8.6)
  Disagree 2 (1.6)
  Strongly disagree 1 (0.8)
I have a good understanding of clinical research.
  Strongly agree 31 (24.2)
  Agree 57 (44.5)
  Neither agree nor disagree 31 (24.2)
  Disagree 3 (2.3)
  Strongly disagree 6 (4.7)
Some clinical research determines by chance what 
treatment a patient receives (randomisation). I am 
comfortable with being randomly assigned (randomised) to 
receive a treatment.
  Strongly agree 24 (18.6)
  Agree 45 (34.9)
  Neither agree nor disagree 35 (27.1)
  Disagree 15 (11.6)
  Strongly disagree 10 (7.8)
Cancer research will help doctors better understand and 
treat cancer.
  Strongly agree 102 (78.5)
  Agree 26 (20.0)
  Neither agree nor disagree 2 (1.5)
  Disagree 0 (0)
  Strongly disagree 0 (0)
The primary reason cancer research is done is to improve 
the treatment of future patients with cancer.
  Strongly agree 86 (66.2)
  Agree 36 (27.7)
  Neither agree nor disagree 3 (2.3)
  Disagree 3 (2.3)
  Strongly disagree 2 (1.5)
I will not directly benefit from participating in cancer 
research.
  Strongly agree 26 (20.0)
  Agree 42 (32.3)
  Neither agree nor disagree 31 (23.8)
  Disagree 28 (21.5)
  Strongly disagree 3 (2.3)
Patients who participate in research studies should be told 
the results when the study is compete.





  Agree 62 (47.7)
  Neither agree nor disagree 20 (15.4)
  Disagree 1 (0.8)
  Strongly disagree 1 (0.8)
I would agree to participate in the SAFETY trial if eligible 
(n=124).
  Yes 106 (85.5)
  No 18 (14.5)
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participation in the background survey was critical. Finally, 
this survey study represents an important step in engaging 
patients in randomised controlled trial development and 
inception, thus improving the patient- centred nature of 
cancer research.
Our study also had some limitations to consider. First, 
there may have been selection bias in that those who agreed 
to participate in the survey study are also more likely to 
participate in research in general. This would overestimate 
the acceptance rate of the SAFETY study and interest in clin-
ical research. However, our response rate was 92%, some-
what mitigating these concerns. Second, the survey was not 
a validated survey; however, it allowed us to determine the 
proportion of participants who would theoretically consent 
to participating specifically in the SAFETY trial, as well as 
investigate patients’ views on the burden of cancer care and 
on cancer research in greater detail than would have been 
possible with standardised questionnaires. Third, the demo-
graphics of the respondents were not diverse with respect 
to race (82.3% white) and continent of residence (93.1% 
from North America). The incidence data collected in the 
Surveillance, Epidemiology and End Results database of 
the National Cancer Institute demonstrate similar rates of 
sarcomas between white and black populations.22–25 This 
is also inconsistent with the overall North American demo-
graphic data, as black individuals comprise approximately 
13% of the North American population.26 27 These demo-
graphic discrepancies somewhat limit the external validity of 
the findings with respect to Europe and other international 
sites. And while it is not uncommon for non- white racial/
ethnic groups to be under- represented in cancer clinical 
trials, the race demographics of this survey have highlighted 
an important gap to address in our recruitment strategy for 
the SAFETY trial.28–30 Fourth, while the survey addressed indi-
rect costs of sarcoma surveillance (such as the cost of travel 
or missed work to attend a clinic visit), it did not address the 
direct costs of surveillance (such as the cost to patients of 
different thoracic imaging techniques or additional imaging 
and clinic visits). However, postoperative sarcoma surveillance 
is considered standard of care despite being highly varied 
among orthopaedic oncologists with respect to thoracic 
imaging and frequency.31–33 Therefore, direct costs should 
not apply to most patients as a wide spectrum of surveillance 
care regimens are within the range of standard practice and 
should be covered by the patients’ federal, provincial/state 
or private health insurance.34 Nevertheless, these cost data 
would likely prove valuable when considering trial participa-
tion of patients without private health insurance in countries 
without socialised healthcare such as the USA. Finally, the 
survey did not evaluate the optimal timing and method to 
approach patients to participate in the SAFETY trial.
Relevance to previous research
The exploration of patients’ perceptions of sarcoma surveil-
lance in the context of a randomised surveillance trial has not, 
to our knowledge, previously been reported. However, as far 
back as 1979, researchers interviewed patients with sarcoma 
to determine reasons for acceptance of randomisation 
in treatment- related clinical trials.35 The authors of this 
study concluded that patient acceptance of participation in 
treatment- related clinical trials was associated with treatment 
factors such as burden of care and drug toxicities. Within the 
field of orthopaedic surgery, Creel et al36 surveyed patients 
with meniscal tears and determined willingness to partici-
pate in a trial in which they would be randomised to opera-
tive versus non- operative treatment. The authors found that 
lack of strong treatment preferences and male gender were 
significantly associated with willingness to participate in such 
a trial. Only 46% of patients reported that they would be defi-
nitely willing or probably willing to participate.
A large survey study of 1227 Swiss patients in which four 
different clinical trial vignettes were described found that all 
studies were not equally acceptable to patients. A higher will-
ingness to participate was found when a new drug was consid-
ered safe, no extra logistical burden of care was required, 
results were openly available to the public and the project was 
approved by a research ethics committee. In contrast, use of 
placebo controls, and random allocation to study arms were 
associated with a lower likelihood of participation.37 Simi-
larly, Halpern et al found that in patients with hypertension, 
inconvenience, fear of known side effects and the possibility 
of receiving placebo were the most common concerns for 
patients in clinical trials.38 Similar to the orthopaedic trial 
outlined above, only 47% of patients would be willing to 
participate in a placebo- controlled trial.
Implications
In this study, we found that a high percentage of patients 
with sarcoma would be willing to participate in surveillance 
research. In comparison to other published patient survey 
studies of treatment- related RCTs, the willingness to partici-
pate identified in this study is significantly greater. This has 
positive implications for sarcoma surveillance research in 
general, and specifically for the SAFETY trial. However, survey 
responses do not necessarily align with actual participation. 
Moreover, the sense of being overwhelmed with the diagnosis 
of sarcoma and the need for intensive treatment can deter 
patients from accepting an additional dimension to their 
care in the form of a trial. Nevertheless, the patient engage-
ment strategy used in this study is likely to increase enrolment 
in the SAFETY trial and help guide study implementation.39
CONCLUSIONS
The results of this patient survey demonstrate that the 
majority of participants would be willing to participate in an 
RCT that evaluates different postoperative sarcoma surveil-
lance regimens. Participants’ motivations for trial participa-
tion included trust in the healthcare system and altruistic 
reasons to help future patients. Those that would decline 
the study for the most part would do so because of the over-
whelming burden of a cancer diagnosis. These results will 
help inform the development of patient- centred clinical trial 
protocols in cancer surveillance research and specifically the 
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